


New Hampshire Coronavirus Disease 2019 Weekly Partner Call



October 14, 2021

*Ben Chan
Stephanie Locke
Elizabeth Talbot
Beth Daly
Lindsay Pierce*

Thursday noon-time partner calls will focus on science, medical, and vaccine updates with time for Q&A

Healthcare Provider & Public Health Partner Calls

- **2nd and 4th Thursday** of each month from 12:00-1:00 pm (next call will be Thursday, October 28th)
- Webinar/call information:
 - Zoom link: <https://nh-dhhs.zoom.us/s/94059287404>
 - Webinar ID: 940 5928 7404
 - Passcode: 353809
 - Telephone: 646-558-8656


Agenda

- Epidemiology
- COVID-19 testing sites
- Molnupiravir (oral antiviral)
- Pfizer-BioNTech COVID-19 vaccine for 5-11 year olds
- Questions & Answers (Q&A)

Epidemiology Update


U.S. National Daily Incidence of COVID-19

Daily Trends in Number of COVID-19 Cases in The United States Reported to CDC




https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases

Number of New COVID-19 Cases per Day in NH




<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

% of Tests (Antigen and PCR) Positive for COVID-19 (7-Day Average)




<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

Number of People Hospitalized with COVID-19 Each Day in NH (Hospital Census)



<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

Average Number of COVID-19 Deaths per Day in NH (Based on Date of Death)



<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

COVID-19 Testing Site Update

COVID-19 Testing Sites

October 2021



NH DIVISION OF
Public Health Services
Department of Health and Human Services



ClearChoiceMD Testing Locations

- ▶ Manchester – Across the street from the JFK Coliseum
 - 303 Beach Street, Manchester
- ▶ Claremont – River Valley Community College
 - 1 College Place, Claremont
- ▶ Newington (Opening soon)
- ▶ Nashua (Opening soon)

Operational Overview

- ▶ Hours of operation
 - 7 days/week
- ▶ No appointment required
- ▶ Drive-up and pedestrian traffic accommodated
 - Manchester is pedestrian traffic only
- ▶ Testing
 - PCR testing
 - Asymptomatic & symptomatic individuals
- ▶ Over-the-phone interpretation and video-remote interpretation services available at all sites

Operational Overview (cont.)

▶ Results process

- Site staff distributes handouts on the results process at the time the sample is collected
 - QR code connects the individual to the online portal
 - ClearChoiceMD will call individuals who do not have internet access
 - Results typically available in 48 hours

▶ Customer Service

- ClearChoiceMD has a call center open 7 days a week from 8am – 8pm
- Additional information is available here:
 - <https://ccmdcenters.com/state-of-nh-covid-19-testing>
 - ClearChoiceMD Call Center: (603) 457-7792

Therapeutics Update

Molnupiravir

- New oral antiviral medicine to treat non-hospitalized adults with mild-moderate COVID-19 who are at risk for advancing to severe disease
- Ribonucleoside analog that inhibits SARS-CoV-2 replication
- Not available for use yet, but it has been submitted to the FDA for Emergency Use Authorization by Merck and Ridgeback Biotherapeutics
- Data on efficacy and safety has not been published

Molnupiravir

- Interim analysis evaluating 775 patients enrolled in the MOVE-OUT trial (randomized placebo-controlled double-blinded multi-site/global Phase 3 clinical trial)
- Recruitment was stopped early due to the positive/beneficial results
- Submitted to FDA for EUA on October 11th



Media > News releases > News release

Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

October 1, 2021 6:00 am ET

<https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/>

Molnupiravir (Interim Analysis)

- Molnupiravir significantly reduced the risk of hospitalization or death by ~50% in non-hospitalized adult patients with mild-moderate COVID-19 who were at risk for severe disease
 - Molnupiravir recipients: 7.3% were either hospitalized or died
 - Placebo recipients: 14.1% were either hospitalized or died
 - Deaths: No deaths occurred in people treated with molnupiravir compared to 8 deaths in people who received the placebo
 - Variants: demonstrated consistent efficacy across genetic variants (including Delta)
- Incidence of adverse events was similar between molnupiravir and placebo groups; fewer participants discontinued therapy in the molnupiravir group (1.3%) compared to the placebo group (3.4%) due to an adverse event

Vaccination (Prevention) vs. Treatment

- COVID-19 vaccination is still the first-line of defense to prevent infection and transmission (and the most important and effective)
- New therapeutics do NOT replace the need for people to get vaccinated, but they are another tool to help limit the impact of infection (particularly on hospitalizations and deaths from COVID-19)

COVID-19 Vaccine Update

Pfizer-BioNTech Vaccine for 5-11 Year Olds

- Pfizer-BioNTech [announced](#) (September 28th) they have submitted data to the FDA on use of their vaccine in children 5-11 years old
- October 7th Pfizer-BioNTech requested Emergency Use Authorization (EUA)
- FDA's VRBPAC (science advisory committee) is scheduled to meet October 26th to review and discuss
- CDC's ACIP scheduled to meet November 2nd and 3rd
- We are anticipating and planning for the Pfizer-BioNTech COVID-19 vaccine to be authorized and recommended for children 5-11 years old by the first week in November

Planning Information

- There are ~28 million children in the U.S. aged 5-11 years
- The U.S. government has enough vaccine to support vaccination of this entire population
- Pfizer-BioNTech COVID-19 vaccine for 5-11 year olds will be a new product with a different dose administered and new packaging
- Vaccine will come in 10-dose vials, distributed in packages of 10 vials (100 total doses)
- Product can be stored for 10 weeks at 2-8°C (undiluted?)
- Product will require dilution (ancillary supplies will be provided)
- Ordering will begin once FDA issues an EUA, and vaccine administration can begin once CDC makes a formal recommendation (based on ACIP recommendations)

Providers Who Want to Administer Vaccine

- Follow the instructions for enrolling to be a COVID-19 vaccine provider: <https://www.covid19.nh.gov/resources/vaccine-information>

In order to enroll as a COVID-19 vaccination provider, download the [Provider Agreement](#)  complete the form electronically, being careful to follow the instructions, and email to C19Enrollment@dhhs.nh.gov.


- [Provider Agreement Instructions](#) 
- [Provider Agreement](#)  *(must be downloaded and opened in Adobe Acrobat, not completed in the web browser)*

Q&A

Healthcare Provider & Public Health Partner Calls

- **2nd and 4th Thursday** of each month from 12:00-1:00 pm (next call will be Thursday, October 28th)
- Webinar/call information:
 - Zoom link: <https://nh-dhhs.zoom.us/s/94059287404>
 - Webinar ID: 940 5928 7404
 - Passcode: 353809
 - Telephone: 646-558-8656

New Hampshire Coronavirus Disease 2019 Weekly Partner Call



October 14, 2021

*Ben Chan
Stephanie Locke
Elizabeth Talbot
Beth Daly
Lindsay Pierce*

Thursday noon-time partner calls will focus on science, medical, and vaccine updates with time for Q&A